Please assess the completion status of the following clinical trial:

Trial Title: Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient admitted to a Danish emergency department, lung medical department or medical department~* Age \>18 years~* Hospitalized \<48 hours~* Positive COVID-19 test/diagnosis during the hospitalization~* Signs informed consent~Exclusion Criteria:~* If the patient uses \> 5 LO2/min at time of recruitment~* Known intolerance/allergy to azithromycin or hydroxychloroquine or hypersensitivity to quinine or 4-aminoquinolinderivates~* Pregnancy~* Breastfeeding~* Neurogenic hearing loss~* Psoriasis~* Retinopathy~* Maculopathy~* Changes in vision field~* Severe liver disease other than amoebiases~* Severe gastrointestinal, neurological or haematological disorders~* eGFR \< 45 ml/min/1.73m2~* Clinically significant cardiac conduction disorders/arrhythmias or prolonged QTc interval~* Myasthenia Gravis~* Uses Digoxin~* Glucose-6-phosphate dehydrogenase deficiency~* Porphyria~* Hypoglycemia at any time since hospitalization~* Severe mental illness which significantly impedes cooperation~* Severe linguistic problems that significantly impedes cooperation~* Treatment with sickle alkaloids

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): This arm will receive standard care and placebo in 15 days.~Azithromycin placebo:~Day 1-3: 500 mg x 1 Day 4-15: 250 mg x 1~Hydroxychloroquine placebo:~Day 1-15: 200 mg x 2
- Intervention (Type: ACTIVE_COMPARATOR): This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.~Azithromycin:~Day 1-3: 500 mg x 1 Day 4-15: 250 mg x 1~Hydroxychloroquine:~Day 1-15: 200 mg x 2

Based on this trial design, predict the completion outcome and termination type (if applicable).